Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges

被引：49

作者：

Ford, Elizabeth ^{[1
,2
,3
]}

Pearlman, Jodie ^{[1
,2
,3
]}

Ruan, Travis ^{[1
,2
]}

Manion, John ^{[1
,2
,4
,5
,6
]}

Waller, Matthew ^{[1
,2
]}

Neely, Gregory G. ^{[1
,2
]}

Caron, Leslie ^{[1
,2
]}

机构：

[1] Univ Sydney, Charles Perkins Ctr, Centenary Inst, Dr John & Anne Chong Lab Funct Genom, Camperdown, NSW 2006, Australia

[2] Univ Sydney, Sch Life & Environm Sci, Camperdown, NSW 2006, Australia

[3] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England

[4] Boston Childrens Hosp, Dept Urol, Boston, MA 02115 USA

[5] Harvard Med Sch, Dept Surg, Boston, MA 02115 USA

[6] Harvard Med Sch, Dept Microbiol, Boston, MA 02115 USA

来源：

CELLS | 2020年 / 9卷 / 11期

基金：

英国医学研究理事会;

关键词：

neurodegenerative diseases; human pluripotent stem cells; cell therapy; regenerative medicine; SPINAL-CORD-INJURY; MIDBRAIN DOPAMINERGIC-NEURONS; FUNCTIONAL RECOVERY; NEUROPATHIC PAIN; TRANSGENIC MICE; ALZHEIMERS-DISEASE; PROGENITOR CELLS; RAT MODEL; HUMAN OLIGODENDROCYTES; GABAERGIC INHIBITION;

D O I：

10.3390/cells9112517

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Neurodegenerative diseases are characterized by irreversible cell damage, loss of neuronal cells and limited regeneration potential of the adult nervous system. Pluripotent stem cells are capable of differentiating into the multitude of cell types that compose the central and peripheral nervous systems and so have become the major focus of cell replacement therapies for the treatment of neurological disorders. Human embryonic stem cell (hESC) and human induced pluripotent stem cell (hiPSC)-derived cells have both been extensively studied as cell therapies in a wide range of neurodegenerative disease models in rodents and non-human primates, including Parkinson's disease, stroke, epilepsy, spinal cord injury, Alzheimer's disease, multiple sclerosis and pain. In this review, we discuss the latest progress made with stem cell therapies targeting these pathologies. We also evaluate the challenges in clinical application of human pluripotent stem cell (hPSC)-based therapies including risk of oncogenesis and tumor formation, immune rejection and difficulty in regeneration of the heterogeneous cell types composing the central nervous system.

引用

页数：34

共 204 条

[51] Delayed Anti-Nogo-A Antibody Application after Spinal Cord Injury Shows Progressive Loss of Responsiveness [J].